Successful treatment using low-dose dasatinib for chronic myelogenous leukemia in a patient with megakaryoblastic transformation concomitant with myelofibrosis and an extramedullary tumor

Leukemia Research

Volumn 34, Issue 9, 2010, Pages

  Yamaguchi, Masaki ^a   Munemoto, Saori ^a   Kasada, Atsuo ^a   Murata, Ryoichi ^a   Ueda, Mikio ^a  

^a ISHIKAWA PREFECTURAL CENTRAL HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; DASATINIB; IMATINIB;

AGED; ANEMIA; BLAST TRANSFORMATION; BLOOD TOXICITY; BONE BIOPSY; BONE MARROW BIOPSY; BONE PAIN; CANCER SURGERY; CASE REPORT; CHRONIC MYELOID LEUKEMIA; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMUR TUMOR; HUMAN; HUMAN CELL; HUMAN TISSUE; LABORATORY TEST; LETTER; LOW DRUG DOSE; MALE; MEGAKARYOBLAST; MEGAKARYOCYTE; MYELOFIBROSIS; MYOFIBROSIS; NEEDLE BIOPSY; NUCLEAR MAGNETIC RESONANCE IMAGING; PHILADELPHIA CHROMOSOME POSITIVE CELL; PRIORITY JOURNAL; THROMBOCYTOPENIA; THROMBOCYTOSIS; TUMOR LOCALIZATION; UNSPECIFIED SIDE EFFECT;

EID: 77955269560     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2010.03.024     Document Type: Letter

References (9)

1. Kantarjian H.M., Sawyers C., Hochhaus A., et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002, 346:645-652.
2. Sawyers C.L., Hochhaus A., Feldman E., et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 2002, 99:3530-3539.
3. Faderl S., Talpaz M., Estrov Z., Kantarjian H.M. Chronic myelogenous leukemia: biology and therapy. Ann Intern Med 1999, 131:207-219.
4. Bourantas K.L., Repousis P., Tsiara S., Christou L., Konstantinidou P., Bai M. Chronic myelogenous leukemia terminating in acute megakaryoblastic leukemia. Case report. J Exp Clin Cancer Res 1998, 17:243-245.
5. Inverardi D., Lazzarino M., Morra E., et al. Extramedullary disease in Ph-positive chronic myelogenous leukemia: frequency, clinical features and prognostic significance. Haematologica 1990, 75:146-148.
6. Kvasnicka H.M., Thiele J., Schmitt-Graeff A., et al. Bone marrow features improve prognostic efficiency in multivariate risk classification of chronic-phase Ph1+ chronic myelogenous leukemia: a multicenter trial. J Clin Oncol 2001, 19:2994-3009.
7. Talpaz M., Shah N.P., Kantarjian H.M., et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006, 354:2531-2541.
8. Hirose Y., Kiyoi H., Iwai M., Yokozawa T., Ito M., Naoe T. Successful treatment with imatinib mesylate of a CML patient in megakaryoblastic crisis with severe fibrosis. Int J Hematol 2002, 76:349-353.
9. Branford S., Rudzki Z., Walsh S., et al. High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood 2002, 99:3472-3475.